Balance Sheet
Cash Flow Statement
Capital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in IntangiblesChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Aclaris Therapeutics (ACRS) Change in Account Payables (2017 - 2025)

Aclaris Therapeutics (ACRS) has 9 years of Change in Account Payables data on record, last reported at $4.0 million in Q4 2025.

  • For Q4 2025, Change in Account Payables rose 233.34% year-over-year to $4.0 million; the TTM value through Dec 2025 reached $8.4 million, up 301.7%, while the annual FY2025 figure was $8.4 million, 301.7% up from the prior year.
  • Change in Account Payables reached $4.0 million in Q4 2025 per ACRS's latest filing, up from $377000.0 in the prior quarter.
  • Across five years, Change in Account Payables topped out at $4.0 million in Q4 2025 and bottomed at -$3.5 million in Q2 2024.
  • Average Change in Account Payables over 5 years is $340450.0, with a median of $1.0 million recorded in 2024.
  • Peak YoY movement for Change in Account Payables: skyrocketed 931.44% in 2021, then tumbled 654.31% in 2024.
  • A 5-year view of Change in Account Payables shows it stood at $2.4 million in 2021, then increased by 13.76% to $2.7 million in 2022, then tumbled by 114.66% to -$394000.0 in 2023, then crashed by 654.31% to -$3.0 million in 2024, then skyrocketed by 233.34% to $4.0 million in 2025.
  • Per Business Quant database, its latest 3 readings for Change in Account Payables were $4.0 million in Q4 2025, $377000.0 in Q3 2025, and $2.4 million in Q2 2025.